We are live on ! Find out more
LAB icon

Standard BioTools

81 hedge funds and large institutions have $217M invested in Standard BioTools in 2017 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 34 increasing their positions, 22 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 22

19% more capital invested

Capital invested by funds: $182M → $217M (+$35.1M)

18% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 11

1% more funds holding

Funds holding: 8081 (+1)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

6% less call options, than puts

Call options by funds: $283K | Put options by funds: $300K

28.09% less ownership

Funds ownership: 123.1%95.01% (-28%)

Holders
81
Holders Change
+1
Holders Change %
+1.25%
% of All Funds
1.84%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
13
Increased
34
Reduced
22
Closed
11
Calls
$283K
Puts
$300K
Net Calls
-$17K
Net Calls Change
-$114K

LAB Hedge Fund Activity: Q4 2017 in Review

81 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q4 2017, worth a combined $217M — up 19% from $182M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new LAB positions and 11 closed out — a net gain of 2 holders — while 34 added to existing stakes and 22 trimmed.

The largest buyer was Levin Capital Strategies, adding an estimated $2.54M. The largest seller was Adage Capital Partners, cutting an estimated $3.54M.

  • 81 institutional investors held Standard BioTools (LAB) as of Q4 2017, up from 80 in Q3 2017.
  • Funds reported $217M of Standard BioTools stock for Q4 2017, up 19% quarter-over-quarter.
  • 13 funds opened new Standard BioTools positions in Q4 2017 and 11 closed out, a net change of +2 holders.
  • The largest Standard BioTools buyer in Q4 2017 was Levin Capital Strategies, an estimated $2.54M added.
  • The largest Standard BioTools seller in Q4 2017 was Adage Capital Partners, an estimated $3.54M sold.

Based on aggregated 13F filings for Q4 2017.